Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

References

• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87. doi:10.1002/hep.2725925069599
   PubMed Web of Science ®Google Scholar
• Ju W, Yang S, Feng S, et al. Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. Virol J. 2015;12(1):109. doi:10.1186/s12985-015-0341-126206422
   PubMed Web of Science ®Google Scholar
• Rao H, Wei L, Lopez-Talavera JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2014;29(3):545–553. doi:10.1111/jgh.1239824090188
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen LM, He M. Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 2017;14(1):41. doi:10.1186/s12985-017-0710-z28231805
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469–477. doi:10.1093/infdis/jis38522811301
   PubMed Web of Science ®Google Scholar
• Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509–516 e501. doi:10.1016/j.cgh.2011.03.00421397729
   PubMed Web of Science ®Google Scholar
• Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18(10):e516–522. doi:10.1111/j.1365-2893.2011.01441.x21914071
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014;60(1):98–105. doi:10.1002/hep.2709524615981
   PubMed Web of Science ®Google Scholar
• Lee MH, Hsiao TI, Subramaniam SR, et al. HCV genotype 6 increased the risk for hepatocellular carcinoma among asian patients with liver cirrhosis. Am J Gastroenterol. 2017;112(7):1111–1119. doi:10.1038/ajg.2017.12328440303
   PubMed Web of Science ®Google Scholar
• Berden FA, Aaldering BR, Groenewoud H, et al. Identification of the best direct-acting antiviral regimen for patients with hepatitis c virus genotype 3 infection: a systematic Review and network meta-analysis. Clin Gastroenterol Hepatol. 2017;15(3):349–359. doi:10.1016/j.cgh.2016.10.03427840182
   PubMed Web of Science ®Google Scholar
• Hu C, Yuan G, Liu J, et al. Sofosbuvir-based therapies for patients with hepatitis C virus infection: real-world experience in China. Can J Gastroenterol Hepatol. 2018;2018:3908767. doi:10.1155/2018/390876730538973
   PubMed Web of Science ®Google Scholar
• Gayam V, Tiongson B, Khalid M, et al. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. Eur J Gastroenterol Hepatol. 2018;30(10):1200–1207. doi:10.1097/MEG.000000000000123330096090
   PubMed Web of Science ®Google Scholar
• Wu DB, Jiang W, Wang YH, et al. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: real-world experience of a retrospective study. J Viral Hepat. 2019;26(3):316–322. doi:10.1111/jvh.1303330380166
   PubMed Web of Science ®Google Scholar
• Hlaing NKT, Nangia G, Tun KT, et al. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar. J Viral Hepat. 2019;26(10):1186–1199. doi:10.1111/jvh.1313331104344
   PubMed Web of Science ®Google Scholar
• Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63(5):1430–1441. doi:10.1002/hep.2847326822022
   PubMed Web of Science ®Google Scholar
• Blanco JR, Rivero-Juarez A. HCV genotype 3: a wolf in sheep’s clothing. Expert Rev Anti Infect Ther. 2016;14(2):149–152. doi:10.1586/14787210.2016.112775726635242
   PubMed Web of Science ®Google Scholar
• Huang R, Rao H, Xie Q, et al. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. J Med Virol. 2019;91(7):1313–1318. doi:10.1002/jmv.2545430861150
   PubMed Web of Science ®Google Scholar
• Cheinquer H, Sette H Jr, Wolff FH, et al. Treatment of chronic HCV infection with the new Direct Acting Antivirals (DAA): first report of a real world experience in Southern Brazil. Ann Hepatol. 2017;16(5):727–733. doi:10.5604/01.3001.0010.271728809742
   PubMed Web of Science ®Google Scholar
• Hezode C, Lebray P, De Ledinghen V, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int. 2017;37(9):1314–1324. doi:10.1111/liv.1338328177199
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135. doi:10.1002/hep.2772625614962
   PubMed Web of Science ®Google Scholar
• Belperio PS, Shahoumian TA, Loomis TP, et al. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol. 2019;70(1):15–23. doi:10.1016/j.jhep.2018.09.01830266283
   PubMed Web of Science ®Google Scholar
• Sarwar S, Tarique S, Aleem A, et al. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan. Eur J Gastroenterol Hepatol. 2019;31(8):1035–1039. doi:10.1097/MEG.000000000000137631274596
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628. doi:10.1056/NEJMoa151261426569658
   PubMed Web of Science ®Google Scholar
• El Serafy MA, Kassem AM, Omar H, et al. APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: systematic review and meta-analysis. Arab J Gastroenterol. 2017;18(2):51–57. doi:10.1016/j.ajg.2017.05.00528579340
   PubMed Web of Science ®Google Scholar
• Karic U, Pesic-Pavlovic I, Stevanovic G, et al. FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - a developing country’s perspective in DAA era. J Infect Dev Ctries. 2018;12(3):178–182. doi:10.3855/jidc.1019031829993
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. European association for the study of the liver. electronic address eee, clinical practice guidelines Panel C, representative EGB, Panel m. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170–1218.32956768
   PubMed Web of Science ®Google Scholar
• Pecoraro V, Banzi R, Cariani E, et al. New direct-acting antivirals for the treatment of patients with hepatitis c virus infection: a systematic review of randomized controlled Trials. J Clin Exp Hepatol. 2019;9(4):522–538. doi:10.1016/j.jceh.2018.07.00431516269
   PubMed Web of Science ®Google Scholar
• Wei L, Lim SG, Xie Q, et al. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, Phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4(2):127–134. doi:10.1016/S2468-1253(18)30343-130555048
   PubMed Web of Science ®Google Scholar
• Tao YC, Deng R, Wang ML, et al. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study. Virol J. 2018;15(1):150. doi:10.1186/s12985-018-1066-830285800
   PubMed Web of Science ®Google Scholar
• Han Q, Fan X, Wang X, et al. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Virol J. 2019;16(1):74. doi:10.1186/s12985-019-1184-y31159813
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982. doi:10.1056/NEJMoa02004712324553
   PubMed Web of Science ®Google Scholar
• Rinaldi L, Perrella A, Guarino M, et al. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. J Transl Med. 2019;17(1):292. doi:10.1186/s12967-019-2033-x31462268
   PubMed Web of Science ®Google Scholar
• Chen Yi Mei SLG, Thompson AJ, Christensen B, et al. Sustained virological response halts fibrosis progression: a long-term follow-up study of people with chronic hepatitis C infection. PLoS One. 2017;12(10):e0185609. doi:10.1371/journal.pone.018560929065124
   PubMed Web of Science ®Google Scholar